ebomi
Colour theme
Sign in
Insider · CIK 0001384859

Kolchinsky Peter

CIK 0001384859 Name as filed on the most recent filing

Filed as Kolchinsky Peter (248)

1,080 transaction lines · from 248 filings · filed 2006-12-29 to 2026-08-14 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised. The 40 most recent are shown; the catalog may hold more for this insider.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

11 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2021-08-12 P, Open-market purchase Eliem Therapeutics, Inc.ELYM 2,440,225, acquired Open Form 4 filing 0001104659-21-106405
2021-08-02 P, Open-market purchase Icosavax, Inc.ICVX 2 lines 39,999,990, acquired Open Form 4 filing 0001104659-21-100106
2021-07-27 P, Open-market purchase Cytek Biosciences, Inc.CTKB 2 lines 50,150,000, acquired Open Form 4 filing 0001104659-21-097601
2021-07-06 P, Open-market purchase Acumen Pharmaceuticals, Inc.ABOS 2 lines 30,000,000, acquired Open Form 4 filing 0001104659-21-090244
2021-07-02 P, Open-market purchase Aerovate Therapeutics, Inc.AVTE 38,999,996, acquired Open Form 4 filing 0001104659-21-089472
2021-06-16 P, Open-market purchase Werewolf Therapeutics, Inc.HOWL 124,140, acquired Open Form 4 filing 0001104659-21-082052
2021-06-15 P, Open-market purchase Janux Therapeutics, Inc.JANX 2 lines 49,999,992, acquired Open Form 4 filing 0001104659-21-082085
2021-06-15 P, Open-market purchase Werewolf Therapeutics, Inc.HOWL 103,056, acquired Open Form 4 filing 0001104659-21-082052
2021-06-14 P, Open-market purchase Werewolf Therapeutics, Inc.HOWL 3,902,201, acquired Open Form 4 filing 0001104659-21-082052
2021-06-02 P, Open-market purchase 89bio, Inc.ETNB 415,530, acquired Open Form 4 filing 0001104659-21-077062
2021-05-28 P, Open-market purchase 89bio, Inc.ETNB 2,318,189, acquired Open Form 4 filing 0001104659-21-074404
2021-05-27 P, Open-market purchase 89bio, Inc.ETNB 666,637, acquired Open Form 4 filing 0001104659-21-074404
2021-05-26 P, Open-market purchase 89bio, Inc.ETNB 872,237, acquired Open Form 4 filing 0001104659-21-074404
2021-05-04 P, Open-market purchase Werewolf Therapeutics, Inc.HOWL 2 lines 27,440,000, acquired Open Form 4 filing 0001104659-21-062442
2021-03-19 P, Open-market purchase Solid Biosciences Inc.SLDB 12,688,439, acquired Open Form 4 filing 0001104659-21-040327
2021-03-15 S, Open-market sale scPharmaceuticals Inc.SCPH 777,788, disposed Open Form 4 filing 0001104659-21-037151
2021-03-12 S, Open-market sale scPharmaceuticals Inc.SCPH 284,816, disposed Open Form 4 filing 0001104659-21-037151
2021-03-11 S, Open-market sale Phathom Pharmaceuticals, Inc.PHAT 31,062,500, disposed Open Form 4 filing 0001104659-21-036301
2021-02-26 P, Open-market purchase Satsuma Pharmaceuticals, Inc.STSA 6,999,998, acquired Open Form 4 filing 0001104659-21-030780
2021-02-09 P, Open-market purchase Vor Biopharma Inc.VOR 2 lines 53,632,188, acquired Open Form 4 filing 0001104659-21-016820
2020-12-03 S, Open-market sale Rhythm Pharmaceuticals, Inc.RYTM 4 lines 6,027,391, disposed Open Form 4 filing 0001104659-20-132451
2020-12-02 S, Open-market sale Rhythm Pharmaceuticals, Inc.RYTM 2 lines 1,002,261, disposed Open Form 4 filing 0001104659-20-132451
2020-10-08 S, Open-market sale Vaxcyte, Inc.PCVX 8,498,065, disposed Open Form 4 filing 0001104659-20-113923
2020-10-07 S, Open-market sale Vaxcyte, Inc.PCVX 5,023,527, disposed Open Form 4 filing 0001104659-20-113923
2020-10-01 S, Open-market sale Vaxcyte, Inc.PCVX 776,705, disposed Open Form 4 filing 0001104659-20-111167
2020-09-30 S, Open-market sale Vaxcyte, Inc.PCVX 6,265,871, disposed Open Form 4 filing 0001104659-20-111167
2020-09-29 P, Open-market purchase PMV Pharmaceuticals, Inc.PMVP 17,100,000, acquired Open Form 4 filing 0001104659-20-109853
2020-09-29 S, Open-market sale Vaxcyte, Inc.PCVX 4,202,987, disposed Open Form 4 filing 0001104659-20-111167
2020-09-24 P, Open-market purchase Orchard Therapeutics plcORTX 2,182,037, acquired Open Form 4 filing 0001104659-20-122542
2020-09-21 P, Open-market purchase Dyne Therapeutics, Inc.DYN 12,540,000, acquired Open Form 4 filing 0001104659-20-107953
2020-09-17 P, Open-market purchase 89bio, Inc.ETNB 36,400,000, acquired Open Form 4 filing 0001104659-20-106989
2020-09-09 S, Open-market sale TG Therapeutics, Inc.TGTX 4,092,738, disposed Open Form 4 filing 0001104659-20-104436
2020-08-21 P, Open-market purchase Orchard Therapeutics plcORTX 2 lines 298,610, acquired Open Form 4 filing 0001104659-20-122542
2020-08-20 P, Open-market purchase Orchard Therapeutics plcORTX 2 lines 288,729, acquired Open Form 4 filing 0001104659-20-122542
2020-08-19 P, Open-market purchase Orchard Therapeutics plcORTX 2 lines 300,989, acquired Open Form 4 filing 0001104659-20-122542
2020-08-18 P, Open-market purchase Orchard Therapeutics plcORTX 213,575, acquired Open Form 4 filing 0001104659-20-122542
2020-08-17 P, Open-market purchase Orchard Therapeutics plcORTX 39,034, acquired Open Form 4 filing 0001104659-20-122542

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 2
  • Open-market sale 9
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Kolchinsky Peter, insider transactions. Retrieved 2026-08-26 from https://ebomi.com/insider/0001384859

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.